Long-Term Outcome of Liver Transplant Recipients (OLT) With Hepatitis C Recurrence (HCVR) Who Achieved Postoperative Sustained Virologic Response (SVR) After Combination Antiviral Therapy (Rx) With and Without the Use of Telaprevir (TVR): A Single Center Experience
C. Fasola, P. Mantry, J. Weinstein, H. Nazario, A. Mubarak, M. Barnes, A. Habib, A. Mejia, R. Dickerman, S. Cheng.
Liver Institute, Methodist Dallas Medical Center, Dallas, TX.
Meeting: 2015 American Transplant Congress
Abstract number: A195
Keywords: Graft failure, Hepatitis C, Liver transplantation, Recurrence
Session Information
Date: Saturday, May 2, 2015
Session Name: Poster Session A: Liver Transplantation: Viral Hepatitis
Session Time: 5:30pm-7:30pm
Presentation Time: 5:30pm-7:30pm
Location: Exhibit Hall E
Related Abstracts
- Hepatitis C Recurrence (HCVR) in Liver Transplant Recipients (OLT): Significant Reduction in Tacrolimus (FK) Dosage Can Be Safely Achieved in Patients Rendered Aviremic after Response-Guided Therapy (RGRx) Using Telaprevir (TVR)
- Results of Response Guided Therapy (RGT) Using Telaprevir in Liver Transplant Recipients with Hepatitis C Virus (HCV) Recurrence: A Single Center Experience of 18 Patients
Aim: Liver allografts of viremic OLT have a higher risk of failure. Timely intervention is necessary. However, long-term outcome reports, especially using newer agents, is lacking. Methods: In a 10-year period, we compared: 19 OLT Rx, for 12 weeks, with TVR + Pegylated interferons (P-IFN) + Ribavirin (RBV) followed with conventional Rx (C-Rx, P-IFN+RBV) for 12-36 weeks. Controls (n=19) received C-Rx for 48 weeks. Matching done for age, gender, genotype (all 1), race, OLT date, non-responders (NR), SVR, immunosuppression (tacrolimus + Mycophenolic acid) and survival. Rx criteria HCVR histology (bx, stages 0-3, Batts&Ludwig classification). Pre and post Rx bx + annual bx and 3-year minimum follow up. Laboratory tests, graft and OLT survivals analyzed. Statitistics: t-, Chi2-tests. Results: No demographic , survival (matched controls) or laboratory differences found. Of note, 13/19 (68%) in TVR group were OLT NR to previous C-Rx. At 3+ years of follow up, there was significantly more HCVR progression in OLT TVR NR than TVR SVR (p < 0.05). Controls also showed differences in HCVR progression, although NS.
Telaprevir + PegIFN +Ribavirin Rx | PegIFN + Ribavirin | |||
Non Responders | SVR | Non Responders | SVR | |
(n = 6) | (n = 13) | (n = 6) | (n = 13) | |
PreRx Stage | 1.5±0.6* | 1.7±1.3 | 2.0±0.9 | 1.9±0.9 |
EndRx Stage | 2.2±0.8 | 2.6±1.3 | 2.8±1.2 | 2.0± |
Last Follow up Stage | 2.7±0.8* | 2.1±1.4 | 2.8±1.2 | 2.0± |
PreRx to Last Bx Difference | 1.2±0.8** | 0.4±0.7** | 0.8±1.0 | 0.2±1.1 |
To cite this abstract in AMA style:
Fasola C, Mantry P, Weinstein J, Nazario H, Mubarak A, Barnes M, Habib A, Mejia A, Dickerman R, Cheng S. Long-Term Outcome of Liver Transplant Recipients (OLT) With Hepatitis C Recurrence (HCVR) Who Achieved Postoperative Sustained Virologic Response (SVR) After Combination Antiviral Therapy (Rx) With and Without the Use of Telaprevir (TVR): A Single Center Experience [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/long-term-outcome-of-liver-transplant-recipients-olt-with-hepatitis-c-recurrence-hcvr-who-achieved-postoperative-sustained-virologic-response-svr-after-combination-antiviral-therapy-rx-with-an/. Accessed January 28, 2021.« Back to 2015 American Transplant Congress